Pioglitazone, as mentioned previously in this review, is a PPARγ agonist (like 15d-PGJ2, Table 1) that is FDA-approved to treat type-2 diabetes and can induce apoptosis in activated T-lymphocytes and anti-inflammatory effects in glial cells. Here, PPARG is linked to type 2 diabetes mellitus.